Tryton launches of stent system for bifurcation lesions in Europe
Tryton Medical, a developer of stent systems for the treatment of cardiovascular disease, has initiated launch of its Side Branch Stent System in Europe.
The Research Triangle Park, N.C.-based Tryton said its system is designed to offer a dedicated strategy for treating atherosclerotic lesions at the site of a bifurcation. The system will be available first in the Netherlands, with additional European countries to follow in the coming months.
TOP Medical of Nuth, Netherlands, has partnered with Tryton to distribute the device in the Netherlands.
“We also look forward to initiating a multi-center prospective study evaluating the Tryton Side Branch Stent in real-life practice in the coming weeks,” said J. Greg Davis, president and CEO of Tryton.
The Research Triangle Park, N.C.-based Tryton said its system is designed to offer a dedicated strategy for treating atherosclerotic lesions at the site of a bifurcation. The system will be available first in the Netherlands, with additional European countries to follow in the coming months.
TOP Medical of Nuth, Netherlands, has partnered with Tryton to distribute the device in the Netherlands.
“We also look forward to initiating a multi-center prospective study evaluating the Tryton Side Branch Stent in real-life practice in the coming weeks,” said J. Greg Davis, president and CEO of Tryton.